News
Beximco Completes Sanofi Bangladesh Acquisition
Nov 17 2021
Beximco Pharmaceuticals Ltd has announced that the company has now completed its acquisition of the majority stake in Sanofi Bangladesh, in line with the company’s strategy to expand core capabilities and product offerings.
Mr Nazmul Hassan MP, Beximco Pharma MD, commented: "The completion of this deal - the second acquisition in Beximco Pharma’s history - is a significant moment. We have a clear strategy to continue our diversification and expansion while strengthening our position as a market-leading pharma company in Bangladesh. The acquisition of a majority stake in Sanofi Bangladesh is precisely in line with this strategy, strengthening our position in key therapeutic areas to drive sustainable revenue and profit growth. We look forward to welcoming over 800 skilled and diligent Sanofi Bangladesh employees to our existing workforce. As an enlarged group, we are excited to continue our growth trajectory by delivering affordable treatments and breakthrough therapies in our growing domestic market."
More information online
Digital Edition
Lab Asia 32.2 April
April 2025
Chromatography Articles - Effects of small deviations in flow rate on GPC/SEC results Mass Spectrometry & Spectroscopy Articles - Waiting for the present to catch up to the future: A bette...
View all digital editions
Events
Apr 22 2025 Hammamet, Tunisia
Apr 22 2025 Kintex, South Korea
Analytica Anacon India & IndiaLabExpo
Apr 23 2025 Mumbai, India
Apr 23 2025 Moscow, Russia
Apr 24 2025 Istanbul, Turkey